Navigation Links
Amsterdam Molecular Therapeutics Announces Results of Extraordinary General Meeting
Date:3/30/2012

AMSTERDAM, The Netherlands, March 30, 2012 /PRNewswire/ --

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced that the Extraordinary General Meeting (EGM) of shareholders was held in Amsterdam, the Netherlands, today in accordance with the EGM Notice of February 17, 2012. At the EGM, shareholders approved all the resolutions proposed for the substantial corporate restructuring and financing transaction, which will result in the assets and certain liabilities being acquired by a newly formed private company, uniQure BV, and the AMT legal entity being liquidated.

The shareholders in uniQure previously included a condition to the transaction that meant an additional € 1.0 million of investment was to be secured by AMT prior to completion. This condition has been waived. Completion of the uniQure transaction is expected to occur in early April 2012. Further details on timing on the uniQure transaction are set out on the company's website.

The resolutions put to the EGM convened in accordance with the Notice were passed by a majority in excess of 99 percent. The detailed voting information and results pursuant to Section 2:120 paragraph 5 of the Dutch Civil Code will be posted on the website http://www.amtbiopharma.com.

About Amsterdam Molecular Therapeutics

AMT is a world leader in the development of human gene based therapies. AMT has a product pipeline of gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate probably the world's first stable and scalable AAV manufacturing platform. This proprietary platform can be applied to a large number of rare (orphan) diseases caused by one faulty gen
'/>"/>

SOURCE Amsterdam Molecular Therapeutics (AMT) B.V
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Amsterdam Molecular Therapeutics Reports Promising Data From Cholesterol Lowering Gene Therapy Study
2. Pharma and Food Thought Leaders Set to Converge in Amsterdam Next April 2011
3. Amsterdam Molecular Therapeutics Receives Opinion on Glybera(R) Marketing Authorisation Application
4. Amsterdam Molecular Therapeutics Glybera(R) Significantly Reduces the Risk of Pancreatitis in LPLD Patients
5. Amsterdam Molecular Therapeutics Receives Orphan Designation in the European Union for Hemophilia B Gene Therapy
6. Amsterdam Molecular Therapeutics Announces European Commission Delays Decision on Glybera® Marketing Authorisation and Requests Further Information From the CHMP
7. Amsterdam Molecular Therapeutics Receives Request for Further Information From CHMP on Glybera®
8. Regado Biosciences, Inc. to Present at the BIO-Europe Spring® 2012 Conference in Amsterdam, The Netherlands
9. 8th Annual World Health Care Congress Set for Amsterdam, Spring 2012
10. BD Announces FDA 510(K) Submission of Rapid Molecular Test to Identify Patients Carrying Staph Superbug Prior to Surgery
11. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 2013  Recent regulatory and budget challenges have made ... at large pharmaceutical companies to effectively educate doctors and ... of their new products. With the pressure to reduce ... that these "Med Ed" groups find practical, ... address the changes that are transforming the Medical Education ...
(Date:6/18/2013)... , June 18, 2013 Unilife Corporation ... based designer, developer and manufacturer of injectable drug delivery ... website at www.unilife.com . The new site includes ... updates to occur on a regular basis. ... stated, "As an emerging global leader for injectable drug ...
(Date:6/18/2013)... , June 18, 2013  Specialty ... significant breakthrough in Parylene coating technologies: SCS ... the benefits of Parylene with antimicrobial properties ... devices and components. (Logo: ... infections (HAIs) increase and continue to pose ...
Breaking Medicine Technology:Though Vital to Educating Doctors on New Products, Pharma "Med Ed" Groups Working Under Huge Internal & External Constraints 2Unilife Launches New Corporate Website 2Specialty Coating Systems Announces New Antimicrobial Parylene Technology 2
... All pre-specified subset analyses of progression-free survival,in the ... in,relative risk of disease progression for patients receiving,satraplatin. ... as presence or absence of pain. -- The ... - radiologic,progression and pain progression - were each ...
... ,Abstracts: 2000, 2002 , CHICAGO/DARMSTADT, Germany, June 4, ... today at the American Society of,Clinical Oncology (ASCO) ... cilengitide in patients with newly diagnosed,glioblastoma – a ... highly selective integrin inhibitor targeting the,tumor and its ...
Cached Medicine Technology:Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 2Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 3Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 4Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 5Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 6Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 7Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 2Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 3Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 4Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 5
(Date:6/19/2013)... 2013 At a Travel Services Member Conference, ... growth that has occurred over the last year since he ... said, "Travel Services has added vendors, lowered prices of travel ... Membership is up, even in the tough economy, and they've ... members." , Having been in the Travel Business and Timeshare ...
(Date:6/19/2013)... The motor neuron disease Amyotrophic lateral sclerosis (ALS), also ... sequential pattern which can be classified into four distinct ... at the University of Pennsylvania in the Annals ... and spinal cord tissues shows, for the first time, ... starting point in the central nervous system to other ...
(Date:6/19/2013)... from a naturally occurring compound (apocynin), has been ... Parkinson,s Disease symptoms by preventing deficits in motor ... May 28, 2013 edition of Neuroscience ... fellow at the Medical College of Wisconsin (MCW), ... Balaraman Kalyanaraman, Ph.D., Harry R. & Angeline E. ...
(Date:6/19/2013)... Imprivata ®, a leading global provider ... Imprivata OneSign ® leads the single sign-on (SSO) category ... & Services report . CIOs and other healthcare executives ... performance of its products and the quality of its ... is integral to their long-term healthcare IT strategy. ...
(Date:6/19/2013)... 19, 2013 The US Food and Drug ... ultra cohesive gel breast implant, Mentor Worldwide’s MemoryShape™. , The ... February 2013. The FDA announced the approval of the MemoryShape™ ... primary augmentations in women 22 years old or ... , The FDA’s approval comes after six years of ...
Breaking Medicine News(10 mins):Health News:Former Owner Eric Shuman Endorses New Owners and Changes Made in Last Year Since Shuman Sold Travel Services Center at Member Conference 2Health News:Staging system in ALS shows potential tracks of disease progression, Penn study finds 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 3Health News:FDA Approved Mentor® MemoryShape™ Breast Implants Now Offered to Patients at Swan Center for Plastic Surgery 2
... between the ages of 40 and 59 could substantially reduce ... the September 9 online issue of the Journal of ... are regularly used in developed countries where the incidence of ... is in place. The value and practicality of such screening ...
... ARBOR, Mich.---Pregnant women who take high levels of daily calcium ... blood, suggesting calcium could play a critical role in reducing ... University of Michigan shows that women who take 1,200 milligrams ... in lead levels. , Women who used lead-glazed ceramics and ...
... still giving them to new moms , , TUESDAY, Sept. ... the majority of East Coast hospitals report giving formula ... medical organizations oppose this practice. , The study, ... of Pediatrics & Adolescent Medicine , surveyed 1,295 ...
... Physician Recruitment Firm Will Grow Through Leadership Development and ... ... Alpharetta, Ga. (Vocus) September 9, 2008 -- ... Jackson president of Alpharetta, Ga.-based http://www.locumtenens.com/new_leader08 [LocumTenens.com]. ...
... that sugar,makes good foods taste better, helps breads rise, ... jams and jellies. But,did you know the same preserving ... heal wounds?, Sugar is one of Mother Nature,s ... sugar an excellent food preservative also bestow,it with its ...
... may be better able to comply with medication regimens ... tables that track what they take and when they ... "medtable" may help to prevent medication-related problems. A report ... Experimental Psychology: Applied, published by the American ...
Cached Medicine News:Health News:Breast cancer screening may lower mortality and disease burden in India 2Health News:Calcium during pregnancy reduces harmful blood lead levels 2Health News:Formula Samples Hinder Breast-Feeding Efforts 2Health News:R. Shane Jackson Named President of LocumTenens.com 2Health News:R. Shane Jackson Named President of LocumTenens.com 3Health News:Sugar's Healing Powers 2Health News:Older adults can take medicines more safely and effectively by charting their daily routines 2Health News:Older adults can take medicines more safely and effectively by charting their daily routines 3
... a 60 watt diode continuous wave laser with ... Power Bar technology and 940 nm wavelength make ... for varicose veins and a variety of surgical ... safety features including the LPS, Light guide Protection ...
... is an instrument and LIS independent connectivity ... to work more efficiently than ever. It ... solution that stands between instrument or medical ... important gaps in functionality between the two, ...
70 discs to investigate acquired color deficiency. Quantifies neutral zone characteristics of dyschromatopsia and evaluates the relative luminance....
... the Farnsworth 100 Hue Test comes boxed in ... reduces the potential for test disruption by ... 100 Hue test from Richmond Products includes 93 ... a durable laminated score template for copying, a ...
Medicine Products: